Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab

This study aims to evaluate the effectiveness of a cardiac rehabilitation protocol, incorporating aerobic and resistance exercise, in reducing the incidence of cardiotoxicity in breast cancer patients receiving treatment with anthracyclines and/or trastuzumab through a randomized, active control group, open-label clinical trial.

NCT Number	NCT06881940
Lead Sponsor	Instituto Nacional de Cardiologia Ignacio Chavez Collaborators: Instituto Nacional de Cancerologia de Mexico
Conditions	Cancer Therapy-Related Cardiac Dysfunction
Enrollment	284 participants
Start Date	2025-04-01
Primary Completion	2028-12-01 (estimated)
Study Completion	2029-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-18